Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy
- Resource Type
- Article
- Source
- In
Blood Cells, Molecules and Diseases July 2019 77:88-94 - Subject
- Language
- ISSN
- 1079-9796